Paper Details

  1. Home
  2. Paper Details

Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the effectiveness of isoniazid for preventing tuberculosis in 28,000 people with lung lesions suggestive of the disease. A 24-week course of isoniazid reduced the risk of tuberculosis by two-thirds compared to placebo. While a 52-week course provided the greatest protection, a 24-week course was more efficient in terms of preventing tuberculosis per case of hepatitis, a rare but more common side effect of isoniazid. This suggests that a 24-week course of isoniazid could be a good balance of benefit and risk, particularly where preventative treatment is not currently widespread.
Paper Details　
Original Abstract of the Article :
A total of 28 000 persons with fibrotic pulmonary lesions compatible with tuberculosis were followed for five years after receiving 12, 24, or 52 weeks of preventive treatment with isoniazid or placebo.Compared with placebo, 12 weeks of isoniazid eliminated less than one-third, and 24 weeks eliminat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2536088/

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Tuberculosis Prevention: A Quest for Optimal Regimen

The prevention of [tuberculosis (TB)] remains a pressing concern, with millions worldwide at risk. This research delves into the effectiveness of different durations of [isoniazid preventive therapy] for TB. The study, conducted by the [International Union Against Tuberculosis Committee on Prophylaxis], followed [28,000 individuals with fibrotic pulmonary lesions] for five years, analyzing the impact of [12, 24, or 52 weeks of isoniazid or placebo] treatment. The results offer valuable insights into optimizing TB prevention strategies, aiming to balance effectiveness against potential side effects.

A 24-Week Oasis: Finding the Right Balance

The researchers discovered that [24 weeks of isoniazid] significantly reduced the risk of TB compared to placebo, eliminating [two-thirds] of the risk. This finding suggests that adopting a 24-week regimen could decrease the incidence of TB by [65%] in populations where preventive treatment is not currently practiced. However, the study also highlighted that [hepatitis], a serious side effect, occurred more frequently in those receiving isoniazid. Despite this, the researchers concluded that [24 weeks of isoniazid] prevented more TB cases per case of hepatitis caused. This finding opens the door for a more nuanced approach to TB prevention, balancing the potential benefits against the risks.

A Desert Journey of TB Prevention: Choosing the Right Path

The findings of this study provide valuable information for individuals at risk of TB, particularly in regions where preventive treatment is not widely implemented. The research underscores the importance of finding the [optimal duration of isoniazid treatment], balancing the benefits of prevention against potential side effects. Like a wise camel navigating a vast desert, it's crucial to choose the right path, considering the potential risks and rewards along the way. By understanding the nuances of TB prevention, we can pave the way for a healthier future for those vulnerable to this disease.

Dr. Camel's Conclusion

This study offers a valuable roadmap for TB prevention, emphasizing the importance of finding the right balance between effectiveness and safety. By meticulously analyzing the impact of various isoniazid treatment durations, researchers have provided crucial insights into optimizing TB prevention strategies. Like a camel adapting to the harsh desert environment, we must continuously adapt our approach to combat TB and ensure the health and well-being of those at risk.

Date :
  1. Date Completed 1983-01-07
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

6754120

DOI: Digital Object Identifier

PMC2536088

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.